

Special Issue

Advances in Interventional Radiology in Oncology

Message from the Guest Editor

Since the early 20th century, interventional radiology (IR) has evolved greatly, especially in the oncological setting. The arsenal of modalities at work in IR includes X-ray radiography and fluoroscopy, CT, MRI, US, PET/CT, PET/MRI, and molecular and multimodality imaging within hybrid interventional environments. These techniques have proven to be valuable for the early detection and precise localization of tumor lesions, the accurate determination of tumor stages, and the monitoring of treatment responses. Current advances in the development of personalized therapeutic concepts in the oncological context are closely linked to image-based precision medicine. Interventional radiology (IR) will enable new interventional approaches requiring high-precision guidance and quantitative evaluation. This Special Issue will briefly review the major developments in imaging technology in IR and highlight the role of emerging imaging technologies in enabling high-precision interventions. We encourage researchers to submit original articles and reviews to aid in the development of optimal treatment options for cancer.


Guest Editor

Prof. Dr. Alberta Cappelli

Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy

Deadline for manuscript submissions

25 January 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed




mdpi.com/si/205378

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).